PDE10A has been proposed as an early biomarker and therapeutic target for HD based on the evidence that decreased levels of PDE10A expression occur before the onset of motor-related HD symptoms in transgenic HD mice [6]. The gene discussed is PDE10A; the disease is Huntington disease.